Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recaticimab + lipid-lowering agents
- Development stage
- Unknown
- Lead developer
- Jiangsu HengRui Medicine Co., Ltd.
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous (recaticimab), Oral (statins And Other Lipid-lowering Agents)
01
Overview
This combination therapy consists of **recaticimab (SHR-1209)**, a humanized immunoglobulin G1 monoclonal antibody that targets **proprotein convertase subtilisin/kexin type 9 (PCSK9)**, administered alongside standard **lipid-lowering agents** (primarily statins such as atorvastatin). Recaticimab binds PCSK9 with high affinity, preventing its interaction with LDL receptors and thereby increasing LDL receptor recycling, which lowers plasma LDL cholesterol. The combination, studied as add-on therapy, has demonstrated dose-dependent and sustained reductions in LDL-C levels in patients with hypercholesterolemia or mixed hyperlipidemia, with favorable outcomes observed in other lipid parameters and an overall safety profile comparable to placebo. Developed primarily for long-term management of dyslipidemia and potential reduction of cardiovascular risk[1][2][3][5].
- Other names
- SHR-1209 + lipid-lowering agents
02
Targets
PCSK9 (Proprotein convertase subtilisin/kexin type 9)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on recaticimab + lipid-lowering agents.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recaticimab + lipid-lowering agents.